knowledge -WSS

knowledge

author：entertainment 2025-10-01 11:45:24 - browse：28781

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Pregnancy discrimination could be enabled by AI

hotspot

WSS

Lawsuit highlights wrinkle for disputes over surprise medical bills

Spinal cord stimulation reduces pain in amputees, study finds

WHO recommends second malaria vaccine

What we owe ALS patients — and why one company fell short

Experts study whether long Covid risk adds up with each reinfection

New oral drug delivery patch is modeled after octopus tentacles

focus

knowledge

Wikipedia

Activists slam private health insurers over coverage restrictions

AI models in health care face new federal disclosure requirements

George Santos makes 1st court appearance after pleading not guilty to 13 counts

STAT letters to the editor on burnt

Apple is now the first public company to be valued at $3 trillion

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

After affirmative action ruling, medical educators look to 'holistic review'

Why sickle cell disease is getting the first CRISPR treatment

Drug repurposing or repositioning? The language matters

CMS should re

explore

Radiology is caught between AI's potential and concern for patients

RSV injection headlines need to be accurate for good uptake

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

What will Novo Nordisk's VC do with its influx of cash?

European officials brace for rough respiratory virus season

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

hotspot

leisure time

hotspot

explore